ArticleVascular health and risk management2026
Utility of Novel Lipid Parameters for Risk Stratification in Patients with Diabetes and STEMI-from a Prospective Study.
Article in Vascular health and risk management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Abnormalities in glucose and lipid metabolism are prevalent among individuals suffering from myocardial infarction, with insulin resistance playing an integral role in these pathological processes. This study aims to follow up on incident ischemic stroke events to evaluate whether any alterations in risk estimation merit a reassessment of therapeutic strategies. Herein, we present findings derived from a prospective cohort engaged in this ongoing investigation. Material and Methods: In our analysis, three novel lipid biomarkers-namely proprotein convertase subtilisin/kexin type 9, fatty acid-binding protein 4, and Resolvin D1-emanating from diverse pathophysiological pathways were meticulously evaluated alongside six conventional lipid parameters within a population cohort comprising 1580 individuals, both diabetic and non-diabetic. Results: 1) Furthermore, among DM patients, group 1 (0-1 lipid parameters increased) and group 2 (2-4 lipid parameters increased) had significantly better ischemic stroke-free survival than other groups (p=0.025) when TyG index ≥median. 2) Adding novel lipid associated parameters and TyG index to the conventional lipid risk factors model in the cohort validated it by improved net reclassification index (p<0.05) and integrated discrimination improvement and led to significant reclassification of individuals into risk categories. Conclusion: The incorporation of a biomarker score that encompasses innovative lipid-associated biomarkers alongside the TyG index into a traditional risk assessment framework significantly enhanced the evaluation of ischemic stroke events within myocardial infarction populations afflicted by diabetes mellitus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.